0001493152-20-012892.txt : 20200709 0001493152-20-012892.hdr.sgml : 20200709 20200709092302 ACCESSION NUMBER: 0001493152-20-012892 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20200709 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200709 DATE AS OF CHANGE: 20200709 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TearLab Corp CENTRAL INDEX KEY: 0001299139 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 593434771 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51030 FILM NUMBER: 201019677 BUSINESS ADDRESS: STREET 1: 9980 HUENNEKENS ST. STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-794-1400 MAIL ADDRESS: STREET 1: 9980 HUENNEKENS ST. STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: OccuLogix, Inc. DATE OF NAME CHANGE: 20040730 8-K 1 form8-k.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

 

July 9, 2020

 

 

 

TEARLAB CORPORATION

(Exact name of registrant as specified in its charter)

 

DELAWARE   000-51030   59-343-4771
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
 

(IRS Employer

Identification No.)

 

150 La Terraza Blvd., Ste 101

Escondido, CA

 

 

92025

(Address of principal executive offices)   (Zip Code)

 

(858) 455-6006

(Registrant’s telephone number, including area code)

 

No Change

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 
 

 

Item 2.01. Completion of Acquisition or Disposition of Assets.

 

On July 9, 2020, Accelmed Partners II LP, a Cayman Islands exempted limited partnership (“Buyer”), completed the previously announced acquisition of TearLab Corporation, a Delaware corporation (the “Company”). Pursuant to the terms of the Agreement and Plan of Merger, dated May 11, 2020 (the “Merger Agreement”), among Buyer, the Company and Accelmed Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Buyer (“Merger Sub”), Merger Sub merged with and into the Company (the “Merger”) with the Company surviving the Merger and becoming a wholly owned subsidiary of Buyer, subject to the terms and conditions set forth therein.

 

At the effective time of the Merger (the “Effective Time”) and pursuant to the terms and conditions of the Merger Agreement, (a) each issued and outstanding share of Company common stock and preferred stock that was then owned by Buyer, Merger Sub, certain affiliate funds of CRG L.P. (“CRG”), or any of their respective affiliates, or the Company or any of its subsidiaries (collectively, “Cancelled Shares”) was cancelled for no consideration, and (b) each issued and outstanding share of Company common stock and preferred stock (other than Cancelled Shares) was cancelled and automatically converted into the right to receive an amount equal to $0.0586 per share in cash, without interest and less any required withholding taxes (the “Merger Consideration”). The Company’s common stock is no longer quoted on the OTCQB effective as of the close of trading on July 9, 2020.

 

At the Effective Time, and pursuant to the terms and conditions of the Merger Agreement, each stock option of the Company that was outstanding and unexercised immediately prior to the Effective Time, whether or not then vested or exercisable, was cancelled without any consideration payable therefor and each holder of such stock options ceased to have any rights with respect to such stock options.

 

The foregoing description of the effects of the Merger and the Merger Agreement, and the transactions contemplated thereby, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Merger Agreement. A copy of the Merger Agreement was attached as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the U.S. Securities Exchange Commission (the “SEC”) on May 11, 2020 and is incorporated herein by reference.

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

The information set forth in Item 2.01 of this Current Report on Form 8-K is incorporated into this Item 3.01 by reference.

 

On July 9, 2020, the Company notified the OTCQB of the effectiveness of the Merger. Trading of Company common stock on the OTCQB, which traded under the symbol “TEAR,” was suspended as of the close of trading on July 9, 2020.

 

Item 3.03. Material Modification to Rights of Security Holders.

 

The information set forth in Items 2.01 and 3.01 of this Current Report on Form 8-K is incorporated into this Item 3.03 by reference.

 

As a result of the Merger, each issued and outstanding share of Company common stock and preferred stock immediately prior to the Effective Time (other than (a) shares that were then owned by Buyer, Merger Sub, certain affiliate funds of CRG L.P. (“CRG”), or any of their respective affiliates, or (b) shares that were then owned by the Company or any of its subsidiaries), was cancelled and automatically converted into the right to receive the Merger Consideration.

 

Item 5.01. Changes in Control of Registrant.

 

The information set forth in Items 2.01 and 5.02 of this Current Report on Form 8-K is incorporated into this Item 5.01 by reference.

 

 
 

 

On July 9, 2020, as a result of the Merger, a change in control of the Company occurred, and the Company became a wholly owned subsidiary of Buyer. Buyer paid approximately $736,053.21 in cash to the Company’s shareholders pursuant to the Merger Agreement to acquire the Company. Buyer funded the payment of the aggregate Merger Consideration with cash on its balance sheet.

 

The Company intends to file with the SEC, on Form 15, a certification and notice of termination of the registration of such shares of common stock under Section 12(g) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and suspension of its obligations to file reports under Sections 13 and 15(d) of the Exchange Act.

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Pursuant to the terms of the Merger Agreement, at the Effective Time, each of the members of the Board of Directors of the Company, Joseph Jensen, Elias Vamvakas, Richard Lindstrom, Anthony Altig and Paul Karpecki, resigned from the Board of Directors of the Company and Uri Geiger, the director of Merger Sub at the Effective Time, became the director of the surviving corporation. Additionally, at the Effective Time, the officers of Merger Sub (comprised of Uri Geiger as President and as Secretary) became the officers of the surviving corporation.

 

Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

The information set forth under Item 2.01 of this Current Report on Form 8-K is incorporated into this Item 5.03 by reference.

 

In accordance with the Merger Agreement, at the Effective Time, the certificate of incorporation and bylaws of Merger Sub as in effect immediately prior to the Effective Time, as adjusted pursuant to the Merger Agreement, became the certificate of incorporation and bylaws, respectively, of the Company.

 

Copies of the certificate of incorporation and bylaws of the Company as in effect at the Effective Time are attached hereto as Exhibit 3.1 and Exhibit 3.2, respectively, and are incorporated herein by reference.

 

Item 8.01 Other Events.

 

On July 9, 2020, the Company issued a press release announcing the completion of the Merger, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.
  Description
     
2.1*   Agreement and Plan of Merger, dated May 11, 2020, by and among Buyer, Merger Sub, and the Company, is incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC by TearLab Corporation on May 11, 2020.
3.1   Amended and Restated Certificate of Incorporation of TearLab Corporation
3.2   Amended and Restated Bylaws of TearLab Corporation
99.1   Press Release of TearLab Corporation dated July 9, 2020

 

* Schedules and annexes have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or annex will be furnished supplementally to the SEC upon request.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 9, 2020

 

 

TearLab Corporation

     
  By: /s/ Michael Marquez
  Name: Michael Marquez
  Title: Chief Financial Officer

 

 

EX-3.1 2 ex3-1.htm

 

Exhibit 3.1

 

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

TEARLAB CORPORATION

 

FIRST: The name of the corporation is TearLab Corporation.

 

SECOND: The registered office of the corporation in the State of Delaware shall be National Registered Agents, Inc., 1209 Orange Street, Wilmington, New Castle County, Delaware 19801. The registered agent at such address shall be National Registered Agents, Inc.

 

THIRD: The purpose of the corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

 

FOURTH: The total number of shares of stock which the corporation shall have authority to issue is five thousand (5,000) shares of common stock. All such shares are to be of the par value of $.01 per share.

 

FIFTH: Whenever a compromise or arrangement is proposed between this corporation and its creditors or any class of them and/or between this corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for this corporation under the provisions of Section 291 of the DGCL or on the application of trustees in dissolution or of any receiver or receivers appointed for this corporation under the provisions Section 279 of the DGCL order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of this corporation, as the case may be, and also on this corporation.

 

SIXTH: A director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit. If the DGCL is amended after the filing of the Certificate of Incorporation of which this Article is a part to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. Any repeal or modification of the foregoing paragraph by the stockholders of the corporation shall not adversely affect any right or protection of a director of the corporation existing at the time of such repeal or modification.

 

 

 

 

SEVENTH: The number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. Each director shall be entitled to one (1) vote on each matter presented to the Board.

 

EIGHTH: Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.

 

NINTH: To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which the DGCL permits the Corporation to provide indemnification) through provisions of the Bylaws of the Corporation, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the DGCL.

 

Any amendment, repeal or modification of the foregoing provisions of this Article shall not (a) adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification or (b) increase the liability of any director of the Corporation with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal or modification.

 

*       *       *       *

 

IN WITNESS WHEREOF, the undersigned has executed this certificate on July 9, 2020.

 

  /s/ Uri Geiger
  Uri Geiger
  President and Secretary

 

 

EX-3.2 3 ex3-2.htm

 

Exhibit 3.2

 

BY-LAWS

OF

TEARLAB CORPORATION

 

1. OFFICES:

 

1.1. The Corporation may have an office or offices at such places as the Board of Directors may from time to time designate.

 

2. MEETING OF STOCKHOLDERS:

 

2.1. The annual meeting of stockholders for the election of directors shall be held at such time and date as may be fixed by the Board of Directors.

 

2.2. Special meetings of the stockholders may be called at any time by the president, and shall be called by the president or secretary on the request in writing, or by vote, of a majority of the directors, or at the request in writing of stockholders of record owning a majority in amount of the capital stock outstanding and entitled to vote.

 

2.3. All meetings of the stockholders may be held at such place or places, within or without the State of Delaware, as may from time to time be fixed by the Board of Directors or as shall be specified and fixed in the respective notices or waiver of notice thereof.

 

3. DIRECTORS:

 

3.1. The property and business of the Corporation shall be managed by, or under the direction of, its Board of Directors, consisting of one or more directors as determined from time to time by resolution of the Board of Directors.

 

3.2. Each director shall hold office until the next annual election, and until such director’s successor is elected and qualified, or until such director’s earlier resignation or removal. Directors shall be elected by the stockholders, except that vacancies in the Board of Directors by reason of death, resignation or otherwise and newly created directorships may be filled for the unexpired term by the remaining directors, though less than a quorum, by a majority vote.

 

4. POWER OF DIRECTORS:

 

4.1. The Board of Directors shall have such general and specific powers as are conferred upon corporations by the General Corporation Law of the State of Delaware, as amended from time to time, subject only to the provisions of the statutes, Certificate of Incorporation, and these By-Laws, which may restrict or deny such powers.

 

 

 

 

5. MEETING OF DIRECTORS:

 

5.1. After each annual election of directors, the newly elected directors may meet for the purpose of organization, the election of officers, and the transaction of other business, at such place and time as may be fixed by the stockholders at the annual meeting, and if a majority of the directors be present at such place and time, no prior notice of such meeting shall be required to be given to the directors. The place and time of such meeting may also be fixed by written consent of the directors. Regular meetings of the Board of Directors may be held without notice at such time and at such place as shall from time to time be determined by the Board of Directors.

 

5.2. Special meetings of the Board of Directors may be called by the president, and shall be called by the president or the secretary at the written request of two directors, by notice to each director given five (5) days prior to the meeting if by mail, or two (2) days prior to the meeting if by telephone, facsimile telecommunication or electronic transmission.

 

5.3. Special meetings of the Board of Directors may be held within or without the State of Delaware at such place as is indicated in the notice or waiver of notice thereof.

 

5.4. A majority of the directors shall constitute a quorum, but a smaller number may adjourn from time to time, without further notice, until a quorum is secured.

 

6. EXECUTIVE AND OTHER COMMITTEES:

 

6.1. The Board of Directors may designate an executive committee and one or more other committees each to consist of one or more of the directors of the Corporation.

 

6.2. Any such committee shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation to the extent provided in the resolution of the Board of Directors, subject to applicable laws.

 

6.3. The executive committee and such other committees shall meet at stated times or on notice to all by any of their own number. They shall fix their own rules of procedure. A majority shall constitute a quorum, but unless otherwise determined by the Board of Directors, the affirmative vote of a majority of the whole committee shall be necessary in every case.

 

7. OFFICERS OF THE CORPORATION:

 

7.1. The officers of the Corporation may be a President, one or more Vice-Presidents, Secretary, Treasurer, and such other officers as may from time to time be chosen by the Board of Directors.

 

7.2. Each officer shall hold office until such officer’s successor is elected and qualified or until such officer’s earlier resignation or removal. Any officer may resign at any time upon written notice to the corporation. Any officer may be removed either with or without cause at any time by the Board of Directors. If the office of any officer or officers becomes vacant for any reason, the vacancy shall be filled by the Board of Directors.

 

8. DUTIES OF THE PRESIDENT: Unless otherwise determined by the Board of Directors,

 

8.1. The President shall be the chief executive officer of the Corporation unless otherwise determined by the Board of Directors. It shall be the President’s duty to preside at all meetings of the stockholders; to have general and active management of the business and the Corporation; to see that all orders and resolutions of the Board of Directors are carried into effect; to execute all contracts, agreements, deeds, bonds, mortgages and other obligations and instruments, in the name of the Corporation, and to affix the corporate seal thereto when authorized by the Board of Directors or the executive committee.

 

 

 

 

8.2. The President shall have the general supervision and direction of the other officers of the Corporation and shall see that their duties are properly performed and shall have the general duties and powers of supervision and management usually vested in the office of the President of a Corporation.

 

9. VICE PRESIDENT: Unless otherwise determined by the Board of Directors,

 

9.1. The Vice-Presidents, in the order designated by the Board of Directors, shall be vested with all powers and required to perform all the duties of the President in the President’s absence or disability and shall perform such other duties as may be prescribed by the Board of Directors.

 

10. PRESIDENT PRO TEM:

 

10.1. In the absence or disability of the President and the Vice-President, the Board of Directors may appoint from their own number a president pro tem.

 

11. SECRETARY: Unless otherwise determined by the Board of Directors,

 

11.1. The Secretary shall attend all meetings of the Corporation, the Board of Directors, the executive committee and standing committees. The Secretary shall act as clerk thereof and shall record all of the proceedings of such meetings in a book kept for that purpose. The Secretary shall give proper notice of meetings of stockholders and Board of Directors and shall perform such other duties as shall be assigned by the President or the Board of Directors.

 

12. TREASURER: Unless otherwise determined by the Board of Directors,

 

12.1. The Treasurer shall have custody of the funds and securities of the Corporation and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Board of Directors.

 

12.2. The Treasurer shall disburse the funds of the Corporation as may be ordered by the Board of Directors, executive committee or President, taking proper vouchers for such disbursements, and shall render to the President and Board of Directors, whenever they may require it, an account of all his transactions as treasurer, and of the financial condition of the Corporation, and at the regular meeting of the Board of Directors next preceding the annual stockholders’ meeting, a like report for the preceding year.

 

12.3. The Treasurer shall keep an account of stock registered and transferred in such manner and subject to such regulations as the Board of Directors may prescribe.

 

 

 

 

12.4. The Treasurer shall give the Corporation a bond, if required by the Board of Directors, in such sum and in form and with security satisfactory to the Board of Directors for the faithful performance of the duties of his office and the restoration to the Corporation, in case of his death, resignation or removal from office, of all books, papers, vouchers, money and other property of whatever kind in his possession, belonging to the Corporation. The Treasurer shall perform such other duties as the Board of Directors or executive committee may from time to time prescribe or require.

 

13. DUTIES OF OFFICERS MAY BE DELEGATED:

 

13.1. In case of the absence or disability of any officer of the Corporation or for any other reason deemed sufficient by a majority of the Board of Directors, the Board of Directors may delegate his powers or duties to any other officer or to any director for the time being.

 

14. CERTIFICATES OF STOCK:

 

14.1. Certificates of stock shall be signed by the Chairman, the Vice Chairman, the President or a Vice-President, and either by the Treasurer, Assistant Treasurer, Secretary or Assistant Secretary. If a certificate of stock be lost or destroyed, another may be issued in its stead upon proof of loss or destruction and the giving of a satisfactory bond of indemnity in an amount sufficient to indemnify the Corporation against any claim. A new certificate may be issued without requiring bond when, in the judgment of the Board of Directors, it is proper to do so.

 

15. TRANSFER OF STOCK:

 

15.1. Upon surrender to the Corporation or the transfer agent of the Corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer, it shall be the duty of the Corporation to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction on its books.

 

16. STOCKHOLDERS OF RECORD:

 

16.1. The Corporation shall be entitled to treat the holder of record of any share or shares of stock as the holder in fact thereof and accordingly shall not be bound to recognize any equitable or other claim to or interest in such share on the part of any other person whether or not it shall have express or other notice thereof, save as expressly provided by the laws of Delaware.

 

17. FISCAL YEAR:

 

17.1. The fiscal year of the Corporation shall be determined by the Board of Directors.

 

18. DIVIDENDS:

 

18.1. Dividends upon the capital stock may be declared by the Board of Directors at any regular or special meeting and may be paid in cash or property or in shares of the capital stock. The Board of Directors may set apart out of any of the funds of the Corporation available for dividends a reserve or reserves for any proper purposes and may alter or abolish any such reserve or reserves.

 

 

 

 

19. CHECKS FOR MONEY:

 

19.1. All checks, drafts or orders for the payment of money shall be signed by the Treasurer or by such other officer or officers as the Board of Directors may from time to time designate. No check shall be signed in blank.

 

20. BOOKS AND RECORDS:

 

20.1. The books, records and accounts of the Corporation except as otherwise required by the laws of the State of Delaware, may be kept within or without the State of Delaware, at such place or places as may from time to time be designated by the By-Laws or by resolution of the Board of Directors.

 

21. NOTICES:

 

21.1. Except as otherwise specifically provided herein or required by law, all notices required to be given to any stockholder, director, officer, employee or agent shall be in writing and may in every instance be effectively given by hand delivery to the recipient thereof, by depositing such notice in the mails, postage paid, or by sending such notice by facsimile telecommunication or electronic transmission. Any such notice shall be addressed to such stockholder, director, officer, employee or agent at his or her last known address as the same appears on the books of the Corporation. The time when such notice is received, if hand delivered, or when such notice is dispatched, if delivered through the mail, by facsimile telecommunication or electronic transmission, shall be the time of the giving of the notice.

 

21.2. A written waiver of any notice, signed by a stockholder, director, officer, employee or agent, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such stockholder, director, officer, employee or agent. Neither the business nor the purpose of any meeting need be specified in such a waiver.

 

22. AMENDMENT:

 

22.1. These By-Laws may be amended, altered, repealed or supplemented at any regular meeting of the stockholders or of the Board of Directors or at any special meeting called for that purpose, by affirmative vote of a majority of the stock issued and outstanding and entitled to vote or of a majority of the whole board of directors, as the case may be.

 

 

 

 

23. INDEMNIFICATION:

 

23.1. Right to Indemnification:

 

23.1.1. Each person who was or is a party to, or is threatened to be made a party to, or is involved in, any action, suit or proceeding, whether civil, criminal, administrative or investigative (“Proceeding”), including without limitation Proceedings by or in the right of the Corporation to procure a judgment in its favor, by reason of the fact that he or she or a person for whom he or she is the legal representative is or was a director or officer of the corporation, or is or was serving at the request of the corporation as a director or officer, employee or agent of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, whether the basis of such Proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent, shall be indemnified and held harmless by the corporation to the fullest extent authorized by the General Corporation Law of the State of Delaware, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent such amendment permits the corporation to provide broader indemnification rights than said law permitted the corporation to provide prior to such amendment) against all expenses, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person in connection therewith. Such right shall be a contract right and shall include the right to be paid by the corporation for expenses incurred in defending any such Proceeding in advance of its final disposition; provided, however, that the payment of such expenses incurred by a director or officer of the corporation in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service to an employee benefit plan) in advance of the final disposition of such Proceeding, shall be made only upon delivery to the corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it should be determined ultimately that such director or officer is not entitled to be indemnified under this section or otherwise.

 

23.2. Right of Claimant to Bring Suit:

 

23.2.1. If a claim under Section 23.1 is not paid in full by the Corporation within sixty (60) days after a written claim has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any Proceeding in advance of its final disposition where the required undertaking has been tendered to the Corporation) that the claimant has not met the standards of conduct which make it permissible under the General Corporation Law of the State of Delaware for the corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the General Corporation Law of the State of Delaware, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) that the claimant had not met such applicable standard of conduct, shall create a presumption that claimant had not met the applicable standard of conduct.

 

23.3. Non-Exclusivity of Rights:

 

23.3.1. The rights conferred by Sections 23.1 and 23.2 shall not be exclusive of any other right which such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, by-law, agreement, vote of stockholders or disinterested directors or otherwise.

 

23.4. Insurance:

 

23.4.1. The corporation may maintain insurance, at its expense, to protect itself and any such director, officer, employee or agent of the corporation or another corporation, partnership, joint venture, trust or other enterprise against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law of the State of Delaware.

 

DATED: July 9, 2020

 

 

EX-99.1 4 ex99-1.htm

 

Exhibit 99.1

 

 

TEARLAB CLOSES ACQUISITION BY ACCELMED PARTNERS

 

Advancing Company’s Plans to Build Comprehensive Dry Eye Care Platform

 

ESCONDIDO, Calif., July 9, 2020 — TearLab Corporation (TearLab), a leader in diagnostics for dry eye disease (DED), today announced their acquisition by Accelmed Partners II (AP-II). As a newly formed private company, TearLab is now positioned to pursue further development of its next-generation Discovery™ platform and seek out targeted acquisition opportunities that support a comprehensive portfolio to better meet DED market dynamics and patient care needs.

 

“We are very excited to close this transaction with TearLab. Over the past years we spent many days listening to ophthalmologists and optometrists and learning their needs. We are investing in an exceptional team that is primed to execute directly against some of the most important and frequently mentioned unmet needs,” commented Accelmed Partners’ General Partner, Lior Shav. “Working together, Accelmed and TearLab management will combine unique skills and expertise to create a stronger company poised to succeed in the DED market.”

 

The global DED market is projected to grow from $4.42 billion in 2018 to $7.73 billion by the end of 2026.1 An increasing number of dry eye clinical trials, new therapeutic options coupled with continued investment in research and development activities, provide strong tailwinds to support this tremendous market opportunity in the coming years.

 

“Diagnosis and management of ocular surface disease, blepharitis, and DED is important, not only because of patient complications associated with these conditions but also our growing awareness of the relationship between DED and quality of vision,” shared Francis S. Mah, MD, Director of Cornea Service at Scripps Clinic (La Jolla, CA) and Chair of ASCRS Cornea Clinical Committee. “I am delighted TearLab is pursuing a comprehensive portfolio as both eyecare professionals and patients alike will benefit from a greater understanding of this disease.”

 

DED is the most common chronic ophthalmic disorder. TearLab’s years of experience and research in DED strongly position the company to provide the eyecare community with meaningful advances in this under-resourced and under-served market.

 

“This is a promising new chapter for TearLab. Our investment into a wider portfolio of DED diagnostics and treatments will not only offer physicians a broader range of DED management strategies, but also strengthen our leadership position as experts in the dry eye space.” stated Seph Jensen, TearLab’s Chief Executive Officer. “The past few months have been extremely difficult for many practices as they recover from the impact of COVID-19. We aim to provide more opportunities for eye care practices to grow their services while enhancing care to patients.”

 

About TearLab Corporation

 

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively testing for disease bio-markers in tears at the point-of-care. The TearLab® Osmolarity Test, to aid in the diagnosis Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System.

 

About Accelmed Partners

 

Accelmed Partners (www.accelmed.com) is a leading U.S. based private equity firm focused on investments in commercial stage HealthTech companies. Accelmed is based in New York City.

 

1. Fortune Business Insights, March 09, 2020

 

MEDIA CONTACT:

 

Katie Arnold

SPRIG Consulting LLC
408-805-0520

katie@sprigconsulting.com

 

 

 

GRAPHIC 5 ex99-1_001.jpg begin 644 ex99-1_001.jpg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